Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 119

Sort by

Sort Order Select

Journal Articles

Uncovering the Genetics of Poor and Exceptional Survivorship after Unrelated Donor Allogeneic Hematopoietic Cell Transplantation (HCT)

Angel Earle, Pankhil Shah, Susan E. Steck, Jiajia Zhang, Nadine El Kalach, Lara E. Sucheston-Campbell, Stephen R. Spellman, Marcelo C. Pasquini, Meilun He, Qianqian Zhu, Theresa E. Hahn, Alyssa I Clay-Gilmour

Blood (2024) 144 (Supplement 1): 930.

https://doi.org/10.1182/blood-2024-205798

Published: 2024

Journal Articles

Addressing Patient Representation in Hematopoietic Cell Transplant Clinical Trials: Insights Gained through the Access Trial

Blood (2024) 144 (Supplement 1): 3672.

https://doi.org/10.1182/blood-2024-198523

Published: 2024

Journal Articles

Measurable Residual Mutated NPM1 before Allogeneic Transplant for Acute Myeloid Leukemia

Blood (2024) 144 (Supplement 1): 2950.

https://doi.org/10.1182/blood-2024-194922

Published: 2024

Journal Articles

OPTIMIZE: A Phase II Study of Reduced Dose Post Transplantation Cyclophosphamide As GVHD Prophylaxis in Adult Patients with Hematologic Malignancies Receiving HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation

Jeffery J. Auletta, Steven M. Devine, Heather E. Stefanski, Stephen R. Spellman, Todd E. Defor, Brent R. Logan, Brandan J. Butler, Mahasweta Gooptu, Brian C. Shaffer, Antonio M. Jimenez Jimenez, Sameem Abedin, Dipenkumar Modi, MHD Monzr M. Al Malki, Rachel J. Cook

Blood (2024) 144 (Supplement 1): 3514.1.

https://doi.org/10.1182/blood-2024-198252

Published: 2024

Journal Articles

Monoallelic Pathogenic Variants in Hemophagocytic Lymphohistiocytosis Genes Are Uncommon and Not Associated with Hematopoietic Cell Transplantation Outcomes in Severe Aplastic Anemia

Maryam Rafati, Lisa J McReynolds, Youjin Wang, Casey Dagnall, Belynda Hicks, Kristine Jones, Stephen R. Spellman, Meilun He, Yung-Tsi Bolon, Stephanie J. Lee, Sharon Savage, Shahinaz M. Gadalla

Blood (2023) 142 (Supplement 1): 2205.

https://doi.org/10.1182/blood-2023-181010

Published: 2023

Journal Articles

HLA-DRB1 Hed Is Associated with Improved Survival and Decreased Relapse in Patients with Hematologic Malignancies Following Allogeneic Hematopoietic Stem Cell Transplant

Christine Camacho-Bydume, Tao Wang, Diego Chowell, Chirag Krishna, Brian C. Shaffer, Steven Marsh, Sophie Paczesny, Shahinaz M. Gadalla, Meilun He, Yung-Tsi Bolon, Stephen R. Spellman, Stephanie J. Lee, Katharine C. Hsu

Blood (2023) 142 (Supplement 1): 2232.

https://doi.org/10.1182/blood-2023-179543

Published: 2023

Journal Articles

Measurable Residual IDH2 before Allogeneic Transplant for Acute Myeloid Leukemia

Blood (2023) 142 (Supplement 1): 424.

https://doi.org/10.1182/blood-2023-186822

Published: 2023

Journal Articles

MAIT Cell Frequencies within PBSC Grafts Are Associated with Donor CMV Serostatus and Age: An Initial Analysis from the DKMS and NMDP Graft Composition Study

Blood (2023) 142 (Supplement 1): 1033.

https://doi.org/10.1182/blood-2023-185153

Published: 2023

Journal Articles

Combined Effect of Unrelated Donor Age and HLA Peptide-Binding Motifs (PBM) Match Status on HCT Outcomes

Rohtesh S. Mehta, Effie W. Petersdorf, Stephen R. Spellman, Stephanie J. Lee

Blood (2023) 142 (Supplement 1): 1045.

https://doi.org/10.1182/blood-2023-173887

Published: 2023

Journal Articles

Measurable Residual IDH1 before Allogeneic Transplant for Acute Myeloid Leukemia

Blood (2023) 142 (Supplement 1): 4316.

https://doi.org/10.1182/blood-2023-186376

Published: 2023

Journal Articles

Is the Youngest Donor Always the Best Choice to Optimize Outcomes for Matched Unrelated Allogeneic Transplant? Improving Precision Using Novel Statistical Methodology

Rodney A. Sparapani, Martin J. Maiers, Stephen R. Spellman, Bronwen E. Shaw, Purushottam W. Laud, Steven M. Devine, Caitrin Bupp, Meilun He, Brent R. Logan

Blood (2023) 142 (Supplement 1): 3552.

https://doi.org/10.1182/blood-2023-181884

Published: 2023

Journal Articles

Measurable Residual FLT3-ITD before Allogeneic Transplant for Acute Myeloid Leukemia

Blood (2023) 142 (Supplement 1): 4325.

https://doi.org/10.1182/blood-2023-178839

Published: 2023

Journal Articles

Cryopreservation Changes the Immune Effector Cell Composition of Peripheral Blood Stem Cell Grafts: An Analysis from the DKMS and NMDP Graft Composition Study

Blood (2023) 142 (Supplement 1): 1036.

https://doi.org/10.1182/blood-2023-179140

Published: 2023

Journal Articles

Persistence of FLT3 -TKD in Blood Prior to Allogeneic Transplant Is Associated with Increased Relapse and Death in Adults with AML in First Remission

Blood (2023) 142 (Supplement 1): 2941.

https://doi.org/10.1182/blood-2023-180121

Published: 2023

Journal Articles

Prediction of Graft-Versus-Host Disease (GVHD) in Recipients of Hematopoietic Cell Transplant(alloHCT) from a Single Mismatched Unrelated Donor Using a Highly Multiplexed Proteomics Assay: MHC-Pepseq

Karamjeet S. Sandhu, John Altin, Tao Wang, Jakob Devos, Medhat Askar, Zachariah DeFilipp, Ketevan Gendzekhadze, Carrie L. Kitko, Stephanie J. Lee, Margaret L. MacMillan, Stephen R. Spellman, Ryotaro Nakamura

Blood (2023) 142 (Supplement 1): 4930.

https://doi.org/10.1182/blood-2023-186724

Published: 2023

Journal Articles

Post-Transplant Cyclophosphamide Eliminates Disparity in GvHD-Free, Relapse-Free Survival and Overall Survival between 8/8 Matched and 7/8 Mismatched Unrelated Donor Hematopoietic Cell Transplantation in Adults with Hematologic Malignancies

Jeffery J. Auletta, Monzr M. Al Malki, Todd DeFor, Brian C. Shaffer, Mahasweta Gooptu, Javier Bolanos-Meade, Ramzi Abboud, Adrienne D. Briggs, Farhad Khimani, Dipenkumar Modi, Richard Newcomb, Elizabeth J. Shpall, Caitrin Bupp, Stephen R. Spellman, Heather E. Stefanski, Antonio M. Jimenez Jimenez, Steven M. Devine

Blood (2023) 142 (Supplement 1): 780.

https://doi.org/10.1182/blood-2023-172722

Published: 2023

Journal Articles

Donor Hematopoietic Cell Telomere Length and Magnitude of Post-HCT Shortening Predict Survival in Early Stage Leukemia and Myelodysplastic Syndrome

Shahinaz M. Gadalla, Hormuzd Katki, Tsung-Po Lai, Casey Dagnall, Caitrin Bupp, Amy Hutchinson, James Anderson, Kyra Mendez, Stephen R. Spellman, Valerie Stewart, Sharon Savage, Stephanie J. Lee, John Levine, Wael Saber, Abraham Aviv

Blood (2023) 142 (Supplement 1): 365.

https://doi.org/10.1182/blood-2023-189396

Published: 2023

Journal Articles

Racial, Ethnic and Socioeconomic Disparity in Outcomes of Patients with Chronic Graft-Versus-Host Disease: A CIBMTR Analysis

Nosha Farhadfar, Zeina Al-Mansour, Tao Wang, Karen Chen, Joseph Pidala, Margaret L. MacMillan, Carrie Lynn Kitko, Stephen R. Spellman, John R. Wingard, Stephanie J. Lee

Blood (2022) 140 (Supplement 1): 5108–5109.

https://doi.org/10.1182/blood-2022-163537

Published: 2022

Journal Articles

Development of a Validated Clinical Risk Score to Predict the Incidence of Acute Graft Versus Host Disease after Allogeneic Hematopoietic Cell Transplantation: A CIBMTR Analysis

Caden Ulschmid, Xiao Li, Tao Wang, Brent Logan, Joseph Pidala, Margaret L. MacMillan, Carrie Lynn Kitko, Stephanie J. Lee, Stephen R. Spellman, Wael Saber

Blood (2022) 140 (Supplement 1): 279–281.

https://doi.org/10.1182/blood-2022-163263

Published: 2022

Journal Articles

Prognostic Impact and Landscape of Mitochondrial DNA Variants in Myelodysplastic Syndromes Undergoing Allogenic Hematopoietic Cell Transplantation

Jing Dong, Christopher Staffi Buradagunta, Tao Zhang, Stephen R. Spellman, Yung-Tsi Bolon, Paul Auer, Wael Saber

Blood (2022) 140 (Supplement 1): 6930–6931.

https://doi.org/10.1182/blood-2022-159738

Published: 2022

NARROW

Uncovering the Genetics of Poor and Exceptional Survivorship after Unrelated Donor Allogeneic Hematopoietic Cell Transplantation (HCT)

Addressing Patient Representation in Hematopoietic Cell Transplant Clinical Trials: Insights Gained through the Access Trial

Measurable Residual Mutated NPM1 before Allogeneic Transplant for Acute Myeloid Leukemia

OPTIMIZE: A Phase II Study of Reduced Dose Post Transplantation Cyclophosphamide As GVHD Prophylaxis in Adult Patients with Hematologic Malignancies Receiving HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation

Monoallelic Pathogenic Variants in Hemophagocytic Lymphohistiocytosis Genes Are Uncommon and Not Associated with Hematopoietic Cell Transplantation Outcomes in Severe Aplastic Anemia

HLA-DRB1 Hed Is Associated with Improved Survival and Decreased Relapse in Patients with Hematologic Malignancies Following Allogeneic Hematopoietic Stem Cell Transplant

Measurable Residual IDH2 before Allogeneic Transplant for Acute Myeloid Leukemia

MAIT Cell Frequencies within PBSC Grafts Are Associated with Donor CMV Serostatus and Age: An Initial Analysis from the DKMS and NMDP Graft Composition Study

Combined Effect of Unrelated Donor Age and HLA Peptide-Binding Motifs (PBM) Match Status on HCT Outcomes

Measurable Residual IDH1 before Allogeneic Transplant for Acute Myeloid Leukemia

Is the Youngest Donor Always the Best Choice to Optimize Outcomes for Matched Unrelated Allogeneic Transplant? Improving Precision Using Novel Statistical Methodology

Measurable Residual FLT3-ITD before Allogeneic Transplant for Acute Myeloid Leukemia

Cryopreservation Changes the Immune Effector Cell Composition of Peripheral Blood Stem Cell Grafts: An Analysis from the DKMS and NMDP Graft Composition Study

Persistence of FLT3 -TKD in Blood Prior to Allogeneic Transplant Is Associated with Increased Relapse and Death in Adults with AML in First Remission

Prediction of Graft-Versus-Host Disease (GVHD) in Recipients of Hematopoietic Cell Transplant(alloHCT) from a Single Mismatched Unrelated Donor Using a Highly Multiplexed Proteomics Assay: MHC-Pepseq

Post-Transplant Cyclophosphamide Eliminates Disparity in GvHD-Free, Relapse-Free Survival and Overall Survival between 8/8 Matched and 7/8 Mismatched Unrelated Donor Hematopoietic Cell Transplantation in Adults with Hematologic Malignancies

Donor Hematopoietic Cell Telomere Length and Magnitude of Post-HCT Shortening Predict Survival in Early Stage Leukemia and Myelodysplastic Syndrome

Racial, Ethnic and Socioeconomic Disparity in Outcomes of Patients with Chronic Graft-Versus-Host Disease: A CIBMTR Analysis

Development of a Validated Clinical Risk Score to Predict the Incidence of Acute Graft Versus Host Disease after Allogeneic Hematopoietic Cell Transplantation: A CIBMTR Analysis

Prognostic Impact and Landscape of Mitochondrial DNA Variants in Myelodysplastic Syndromes Undergoing Allogenic Hematopoietic Cell Transplantation

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only